Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population.
FOLFIRINOX chemotherapy has shown remarkable responses in patients with metastatic pancreatic cancer (MPC), and has significantly improved prognosis. However, FOLFIRINOX is currently not frequently applied in China because of its high incidence of adverse events, and there is no recognized optimization for this therapy in Chinese population. Modification of FOLFIRINOX may be better for its acceptance in China. In this study, we evaluated the efficacy and safety of modified-FOLFIRINOX in patients with MPC. A total of 62 MPC patients were treated with modified-FOLFIRINOX (no Fluorouracil bolus, 85% Oxaliplatin and 75% Irinotecan) between April 2014 and April 2017 in our institute. 40 of them were evaluated, with a response rate of 32.5% (13/40). The frequent grade 3/4 adverse events are neutropenia (29%) and alanine aminotransferase elevation (14.5%). No treatment-related death was observed. The median overall survival and median progression-free survival are 10.3 months and 7.0 months, respectively. In conclusion, modified-FOLFIRINOX had significantly improved tolerance with similar efficacy to FOLFIRINOX. These findings may provide evidence for the use of FOLFIRINOX in Chinese patients with MPC.
['Li|Xiang|X|', 'Ma|Tao|T|', 'Zhang|Qi|Q|', 'Chen|Yi-Gang|YG|', 'Guo|Cheng-Xiang|CX|', 'Shen|Yi-Nan|YN|', 'Sun|Pei-Wei|PW|', 'Li|Guo-Gang|GG|', 'Gao|Shun-Liang|SL|', 'Que|Ri-Sheng|RS|', 'Lou|Jian-Ying|JY|', 'Yu|Ri-Sheng|RS|', 'Yuan|Ying|Y|', 'Wei|Qi-Chun|QC|', 'Wei|Shu-Mei|SM|', 'Zhang|Yun|Y|', 'Zheng|Lei|L|', 'Bai|Xue-Li|XL|', 'Liang|Ting-Bo|TB|']
D000328:Adult D000368:Aged D000971:Antineoplastic Combined Chemotherapy Protocols D002166:Camptothecin D002681:China D005260:Female D006801:Humans D000077146:Irinotecan D008113:Liver Neoplasms D008175:Lung Neoplasms D008207:Lymphatic Metastasis D008297:Male D008875:Middle Aged D060787:Neoplasm Grading D009362:Neoplasm Metastasis D009367:Neoplasm Staging D009944:Organoplatinum Compounds D000077150:Oxaliplatin D010190:Pancreatic Neoplasms D010534:Peritoneal Neoplasms D011379:Prognosis D011446:Prospective Studies D015996:Survival Rate
Metastatic Pancreatic cancer FOLFIRINOX Chemotherapy Dose modification